Discover more from INSIDE PHARMA
Gene therapies been re-branded 'advanced therapies'—the feeding frenzy continues
Even FDAs top vaccine guy, Peter Marks, is in on it!
Keep getting this advanced therapy conference in my mailbox
Every few weeks, I get an email from Terrapinn, asking me to buy a ticket for their 2024 conference on advanced therapies. The speaker list is below:
Scroll down to speakers with the name beginning with ‘M’, and you will see Peter Marks M.D., PhD., Director - Center for Biologics Evaluation and Research (CBER) .
Marks is the person with delegated authority to evaluate and research applications to market new biologics drugs, eg vaccines.
Could this just be a teenty weeny conflict of interest?
Not at all, it’s a massive one!!!
It is also unprecedented for someone in his position to do anything other than fly-in for a Keynote Address, then fly out again. Hobobbing with the regulated was always a no-no.
What about the other speakers?
Now check out the other speakers. Take it from me, none of them have a clue about the complexities of manufacturing and distributing complex biologic products.
Then check out many of the companies—no more than a handful of employees with hopes of capitalising on the latest ‘market opportunity’.
I will leave you with the message I shared yesterday in relation to Lonza’s CEO being fired. Investors in gene therapies will lose their shirts if they keep placing their chips on mRNA injections that have been positioned as the next great white hope.
They. Are. Not.
Check below to discover how easy it is to be conned.
INSIDE PHARMA is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.